# Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

## TL;DR

This study shows that tralokinumab, a treatment for atopic dermatitis, effectively reduces symptoms over 72 weeks, with better results on the lower limbs compared to other body areas.

## Contribution

The study provides real-world evidence of tralokinumab's long-term effectiveness across specific anatomical sites in atopic dermatitis patients.

## Key findings

- Tralokinumab reduced EASI scores consistently across all anatomical sites over 72 weeks.
- Achievement rates of EASI 75 and EASI 100 were highest on the lower limbs compared to other sites.
- EASI 75 achievement rates at Week 72 ranged from 80% to 86.7% across different body sites.

## Abstract

Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with tralokinumab for 72 weeks. Eczema area and severity index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs). Tralokinumab consistently reduced EASI on all anatomical sites. The achievement rates of EASI 75 and 100 on each site gradually increased from Week 4 to Week 72, and those on lower limbs appeared higher compared to the other sites. The percent reductions of EASI throughout 72 weeks appeared slightly lower on head and neck compared to the other sites. Week 72 achievement rate of EASI 75 on head/neck, trunk, upper limbs, or lower limbs was 80.4%, 80%, 80.3%, or 86.7%, while that of EASI 100 was 37.3%, 25.0%, 27.4%, and 40.0%, respectively. Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites.